{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:19:03Z","timestamp":1777519143721,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T00:00:00Z","timestamp":1303084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Children\/adolescents with mature B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL) have an excellent prognosis but relapses still occur. While chromosomal aberrations and\/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect minimal disease (MD). Children\/adolescents with intermediate\u2010risk B\u2010NHL were treated with French\u2010British\u2010American\/Lymphome Malins de Burkitt 96 (FAB\/LMB96) B4 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for MD. Initial specimens were screened for <jats:italic>IGHV<\/jats:italic> family usage with primer pools followed by individual primers to identify MD. Thirty\u2010two diagnostic\/staging specimens screened positive with primer pools and unique <jats:italic>IGHV<\/jats:italic> family primers were identified. Two patients relapsed; first relapse (4\u2003months from diagnosis) was MD\u2010positive at EOI, the second (36\u2003months from diagnosis) was MD\u2010positive at EOT. At EOI, recurrent rates were similar between the MRD\u2010positive and MRD\u2010negative patients (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b740). At EOT, only 13\/32 patients had MRD data available with one relapse in the MRD\u2010positive group and no recurrences in the MRD\u2010negative group (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7077). The study demonstrated molecular\u2010disseminated disease in which Ig<jats:italic>IGHV<\/jats:italic> primer pools could be used to assess MD. This feasibility study supports future investigations to assess the validity and significance of MD screening in a larger cohort of patients with intermediate\u2010risk mature B\u2010NHL.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08681.x","type":"journal-article","created":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T06:30:52Z","timestamp":1303108252000},"page":"758-763","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Minimal disease assessment in the treatment of children and adolescents with intermediate\u2010risk (Stage III\/IV) B\u2010cell non\u2010Hodgkin lymphoma: a children\u2019s oncology group report"],"prefix":"10.1111","volume":"153","author":[{"given":"Bruce","family":"Shiramizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanton","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Kusao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Agsalda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas G.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren","family":"Sanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherrie","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/412163"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.268"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036665"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.838.838","article-title":"Safety, efficacy and rituximab levels following chemoimmunotherapy (rituximab\u2003+\u2003FAB chemotherapy) in children and adolescents with mature B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL): a Children\u2019s Oncology Group report","volume":"112","author":"Cairo M.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.9536","article-title":"Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III\/IV (Group B) and BM+\/CNS+ (Group C) mature B\u2010NHL: a Children\u2019s Oncology Group report","volume":"28","author":"Cairo M.S.","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(95)80166-9"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1318"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.11.031"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07144.x"},{"key":"e_1_2_7_11_1","first-page":"084a","article-title":"Preliminary results of a phase II study of chemoimmunotherapy (rituximab\u2003+\u2003FAB chemotherapy) in children and adolescents with intermediate risk B\u2010cell NHL: a Children\u2019s Oncology Group report","volume":"12","author":"Goldman S.","year":"2008","journal-title":"Annals of Oncology"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.10453"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2009.81"},{"key":"e_1_2_7_14_1","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non\u2010Hodgkin\u2019s lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy S.B.","year":"1980","journal-title":"Seminars in Oncology"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402828"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.3159"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3370"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.312"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200302000-00005"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21823"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08681.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08681.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:22:00Z","timestamp":1697415720000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08681.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,18]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08681.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08681.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,18]]},"assertion":[{"value":"2011-04-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}